At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06185 CANSINOBIO
Noon Closed 01-12 11:58:52
37.520
-0.480
-1.26%
High38.960Low37.340Vol496.20K
Open38.060D1 Closing38.000Amplitude4.26%
Mkt Cap9.27BTradable Cap4.98BTotal Shares247.04M
T/O18.73MT/O Rate0.37%Tradable Shares132.67M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Hong Kong Stock Movement | CANSINOBIO (06185) Rises Nearly 6% Again; 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine Approved for Clinical Trials
Stock News  ·  01-07
Hong Kong Stock Movement | CANSINOBIO (06185) Rises Nearly 6% Again; 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine Approved for Clinical Trials
CanSino Biologics Inc.'s (HKG:6185) last week's 4.5% decline must have disappointed individual investors who have a significant stake
Simply Wall St.  ·  2025-12-30
CanSino Biologics Inc.'s (HKG:6185) last week's 4.5% decline must have disappointed individual investors who have a significant stake
CanSino Biologics Initiates Phase 1 Study of Pediatric Combination Vaccine
MT Newswires Live  ·  2025-12-22
CanSino Biologics Initiates Phase 1 Study of Pediatric Combination Vaccine
CANSINOBIO (06185) Initiates Phase I Clinical Trial for DTcP-Hib-MCV4 Combined Vaccine and Completes First Subject Enrollment
Stock News  ·  2025-12-19
CANSINOBIO (06185) Initiates Phase I Clinical Trial for DTcP-Hib-MCV4 Combined Vaccine and Completes First Subject Enrollment
Southbound Capital Flow Data (T+2) for Dec 8
Stock News  ·  2025-12-08
Southbound Capital Flow Data (T+2) for Dec 8
CanSino Biologics Inc. (06185) Announces November 2025 Monthly Return on Movements in Securities
Bulletin Express  ·  2025-12-03
CanSino Biologics Inc. (06185) Announces November 2025 Monthly Return on Movements in Securities
CanSino (6185) Announces Board and Committee Composition
Bulletin Express  ·  2025-11-27
CanSino (6185) Announces Board and Committee Composition
CanSino Biologics (6185) Announces EGM Results, Amended Articles, and Board Adjustments
Bulletin Express  ·  2025-11-27
CanSino Biologics (6185) Announces EGM Results, Amended Articles, and Board Adjustments
CANSINOBIO (06185): Zuo Min and Ji Xuefeng Elected as Independent Non-Executive Directors
Stock News  ·  2025-11-27
CANSINOBIO (06185): Zuo Min and Ji Xuefeng Elected as Independent Non-Executive Directors
CanSino Biologics Inc. (688185) Announces Cancellation of Treasury Shares, Issued Shares Total 114,372,901
Bulletin Express  ·  2025-11-27
CanSino Biologics Inc. (688185) Announces Cancellation of Treasury Shares, Issued Shares Total 114,372,901
CANSINOBIO (06185) Cancels 406,100 Repurchased Shares
Stock News  ·  2025-11-27
CANSINOBIO (06185) Cancels 406,100 Repurchased Shares
CANSINOBIO (06185) to Cancel 406,100 Repurchased A Shares
Stock News  ·  2025-11-26
CANSINOBIO (06185) to Cancel 406,100 Repurchased A Shares
Benign Growth For CanSino Biologics Inc. (HKG:6185) Underpins Its Share Price
Simply Wall St.  ·  2025-11-20
Benign Growth For CanSino Biologics Inc. (HKG:6185) Underpins Its Share Price
CanSino Biologics Begins Phase 1 Trial of Tuberculosis Booster Vaccine in Indonesia
MT Newswires Live  ·  2025-11-13
CanSino Biologics Begins Phase 1 Trial of Tuberculosis Booster Vaccine in Indonesia
CanSino Biologics (6185) Announces Phase I Clinical Trial Launch and First Patient Enrollment for Inhaled TB Booster in Indonesia
Bulletin Express  ·  2025-11-13
CanSino Biologics (6185) Announces Phase I Clinical Trial Launch and First Patient Enrollment for Inhaled TB Booster in Indonesia
CanSino Biologics Inc. (6185) Announces 2025 Second Extraordinary General Meeting Notice
Bulletin Express  ·  2025-11-11
CanSino Biologics Inc. (6185) Announces 2025 Second Extraordinary General Meeting Notice
CanSino Biologics Inc. (6185) Issues Proxy Form for 2025 Second Extraordinary General Meeting
Bulletin Express  ·  2025-11-11
CanSino Biologics Inc. (6185) Issues Proxy Form for 2025 Second Extraordinary General Meeting
CanSino Biologics (6185) Announces Board of Supervisors Cancellation, Governance Updates, and Director Nominations
Bulletin Express  ·  2025-11-11
CanSino Biologics (6185) Announces Board of Supervisors Cancellation, Governance Updates, and Director Nominations
CanSino Biologics to Use Reserves to Offset Accumulated 1.45 Billion Yuan Losses; Shares Gain 3%
MT Newswires Live  ·  2025-11-10
CanSino Biologics to Use Reserves to Offset Accumulated 1.45 Billion Yuan Losses; Shares Gain 3%
CANSINOBIO (06185) Proposes Using Capital Reserve to Offset Losses
Stock News  ·  2025-11-07
CANSINOBIO (06185) Proposes Using Capital Reserve to Offset Losses

Introduction

Company Name.
CANSINOBIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Issue price:
--